

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the launch of Revanesse® for the U.K. market.

Revanesse®, Prolenium®’s flagship product collection, consists of multipurpose dermal fillers that utilize advanced hyaluronic acid technology. These fillers are designed to restore volume, smooth wrinkles, create fuller-looking lips, and contour facial features.

The Company has entered into a strategic partnership with Prolenium®, a Canadian premium CE and FDA approved dermal filler manufacturer, in January 2024.

The Company believes that the launch of Revanesse® will diversify the Company’s product portfolio in the U.K. market and provide consumers with more comprehensive and personalized medical aesthetic solutions through the synergy and integration of energy-based devices and injectables products, which will meet the aesthetic needs of consumers. The launch of the Product Collection Revanesse® will also strengthen the Company’s leadership in the U.K. and global markets, which will contribute to the revenue growth of the Company.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, September 2, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* *for identification purpose only*